Cardiovascular Screening Test for Lipoprotein(a) Called Into Question
Cardiovascular Screening Test Called Into Question
美国心脏病学会等机构推荐所有成年人检测Lipoprotein(a),但首个针对降Lipoprotein(a)药物pelacarsen的HORIZON研究显示,该药物未能显著降低心血管事件风险,引发争议。医生对是否进行普遍筛查意见不一,部分医生认为应优先进行CT扫描以检测实际可治疗的疾病。
— MedPage Today reporters offer further insights into recently covered topics
by Rachael Robertson, Enterprise & Investigative Writer, MedPage Today
November 20, 2026 • 8 min read
The following is a transcript of the podcast episode:
Rachael Robertson: Hey everybody! Welcome to MedPod Today, the podcast series where MedPage Today reporters take a deeper look into the week's biggest healthcare stories. I'm your host, Rachael Robertson.
Cheryl Clark is kicking off today's episode with her reporting on an ongoing debate on whether to test all adults for Lipoprotein(a). Then, Kristen Monaco will fill us in on major developments in the GLP-1 medication space. To close out, I'll give us a rundown on the latest measles numbers and what it means that the U.S. lost its measles elimination status after 26 years.
A March recommendation from the American College of Cardiology (ACC) and 10 other medical societies for the first time said all adults should have their blood tested for something called Lipoprotein(a), also called Lp(a) or "little a," which is a risk factor you may have never heard of. But many cardiologists and primary care doctors are strongly resisting doing this. Cheryl Clark is here to tell us more.
Cheryl, what is "little a"?
Cheryl Clark: Thanks, Rachael. Yeah, "little a" – this is a component in blood that is believed to be strongly associated with one's risk of getting an earlier cardiovascular event or aortic stenosis. A growing number of studies seem to show that. But it's genetically inherited, so the score you get basically stays the same throughout your whole life. Diet, exercise, lowering low-density lipoprotein (LDL), body mass index (BMI), they don't change it. So for a long time, doctors said there was really nothing they could do about it. So why measure it?
Scores, it turns out, that are higher than 125 nanomoles per liter might just scare people, especially those without established disease or symptoms. And some doctors are reporting otherwise healthy patients, some even in their 70s, with scores in the high 300s or even higher. So it seems like a high score is survivable, but it is scary.
Now, European cardiology associations in 2022 and again in 2025 began to rethink this. The idea was that if you knew your score, you could change other elements in your life that raise your risk, like trying harder to lose weight. I mean, like really try harder to lower LDL, blood pressure, improve your diet, exercise, do all of that stuff.
The American groups, including the ACC and the American Heart Association, in March joined in. They issued similar recommendations in a 134-page document, basically agreeing with the Europeans. So now this is a standard recommendation that everybody, all adults, should get this at least once in their lifetime.
It might be that their thinking was rooted in the fact that now pharmaceutical companies have been developing drugs that lower this "little a," but they needed clinical trials to prove it. They also needed to prove that it would prevent heart disease and strokes, which of course is the point. Why would we do this otherwise? There are at least three drugs in development, so now lots of smart people are pretty darn sure they'd be successful with this drug and save lots of lives. So a few weeks ago, the first drug trial for a drug called pelacarsen was released, but the results were shockingly disappointing.
Robertson: What did they find?
Clark: Well, it was called the HORIZON study. It was a large placebo-controlled trial, and it found no reduced risk in these cardiovascular events. It tested pelacarsen, which did lower "little a," but participants were still getting diagnosed and dying. So there is something else clearly in play that's causing heart disease. Maybe Lp(a) is a marker for something else, or maybe something else is protecting some people. Who knows?
So I asked a lot of doctors, were they ordering these tests? Especially now that we have the HORIZON results, and several said they were. Some said they were just ordering these tests in people with established familial linkages, like genetic predisposition. But many said they vehemently opposed such a universal recommendation or aren't ordering it at all. My own doctor orders it, but said other doctors in her office practice are not.
One cardiologist said otherwise healthy patients are seeing their high scores online in their portals and are freaking out, crying, and thinking they're going to die tomorrow, and they have to spend time reassuring them. One physician told me the committee should have prioritized calcium CT scoring instead of "little a." He thinks CT scoring shows real disease that can be treated. And Rita Redberg, MD, MSc, a prominent cardiologist at UCSF – she's known for less is more approach – called "little a" a useless test.
And by the way, the Centers for Medicare and Medicaid Services has not joined the bandwagon on testing for "little a." It allows regional Medicare jurisdictions across the country to make case by case determinations about whether to cover the tests. So some beneficiaries are going to get stuck with paying for this out-of-pocket.
Robertson: It sounds like there's still a lot of confusion.
Clark: Yes, the bottom line seems to be: live a healthy life. If you get a high score, be thankful and adhere to strategies that we know reduce your LDL and your other risk factors. We'll see in a few years if any of these other three drugs now in clinical trials clarify this complicated issue.
Robertson: Well, thank you so much for your reporting here, Cheryl.
Clark: Thank you, Rachael.
Robertson: Pediatric obesity took center stage at ObesityWeek in National Harbor, Maryland. There were two major phase III trials showing strong weight loss results for GLP-1 medications in kids and teens. This was just days after the FDA added a new vision-related safety warning across the entire drug class. Kristen Monaco is here to break down the latest developments.
So, Kristen, starting with the adolescent data from ObesityWeek, what did the SURMOUNT-ADOLESCENTS trial show for tirzepatide?
Kristen Monaco: SURMOUNT-ADOLESCENTS was a phase III trial simultaneously published in JAMA that looked at the very popular dual GLP-1/GIP receptor agonist tirzepatide, also known as Zepbound, in 160 adolescents ages 12 to 17 with overweight or obesity. All participants also received lifestyle intervention. At week 72, teens who were taking tirzepatide saw an average BMI reduction of 18.5%, compared with a 0.5% increase in those taking placebo. Nearly half on tirzepatide achieved at least a 20% reduction in BMI, and over half were no longer considered to have obesity by the end of the trial.
Notably, researchers also saw improvements in quality of life and physical comfort scores, with no signals of disruption to growth or pubertal maturation, which is a concern of using these agents in this age group. Tirzepatide is currently only approved for adults with obesity or kids 10 and older with type 2 diabetes. So these data lay the groundwork for potential obesity indication in teens. However, rival GLP drug semaglutide is already approved for teens with obesity.
Robertson: Those are really impressive results. Researchers also presented data looking at even younger children, those ages six to 11. What did the STEP Young trial find for semaglutide?
Monaco: STEP Young, which was published in the New England Journal of Medicine, looked at semaglutide, also known as Wegovy, in 167 children, ages 6 to 11, with obesity alongside lifestyle counseling. Right now, semaglutide is only approved for obesity in patients ages 12 and up. There are no GLP-1 therapies right now that are FDA approved for this very young age group. So treatment options are largely limited to lifestyle modifications.
In the trial at week 68, semaglutide reduced BMI by 13.5%, and nearly 40% of children on the injectable no longer had obesity by the end of the trial. Children on treatment also saw improvements in cardiometabolic markers like waist circumference, triglycerides, and blood pressure. Gastrointestinal side effects like vomiting, diarrhea, and nausea were more common, especially during the dose escalation phase, which is expected with GLP-1 drugs. Though they were mostly mild to moderate and transient, with no safety signals affecting growth or pubertal development. Drug maker Novo Nordisk hasn't announced yet whether it plans to submit these data to the FDA, so that will be something to look closely for.
Robertson: That's super interesting. So stepping back from your conference coverage, you also reported on a major regulatory update involving GLP-1 drugs and eye health. What is this FDA warning, and what led to it?
Monaco: Yes, so the FDA is now requiring manufacturers of all currently marketed GLP-1 medications to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy, also known as NAION, which is a rare but potentially blinding eye condition caused by reduced blood flow to the optic disc. This update follows a wave of observational studies, including a 2024 JAMA Ophthalmology study on semaglutide, that prompted this FDA review. The agency concluded from its review that there is indeed a rare but potentially increased risk of NAION events in patients taking GLP-1 drugs. Cases have been reported for all currently marketed GLP-1 products.
So the FDA told healthcare providers to tell their patients to report any sudden, painless vision loss or visual field changes in one eye immediately, and then to refer them promptly to an ophthalmologist. They should also consider discontinuing the GLP-1 drug unless the treatment benefits clearly outweigh the risks.
Robertson: Well, thank you so much for this important context as these medications continue to expand into younger populations. Thanks for being here, Kristen.
Monaco: Thank you, Rachael.
Robertson: The U.S. has officially lost its measles elimination status after 26 years. It's no surprise, considering there have been at least 830 hospitalizations and 13 measles-associated deaths in the past 2 years.
Losing this status is a big deal. Our editor-in-chief, Jeremy Faust, MD, sat down with pediatric infectious disease expert Paul Offit, MD, of Children's Hospital of Philadelphia, and public health researcher Noel Brewer, PhD, of the University of North Carolina in Chapel Hill. They talked about the resurgence of measles outbreaks, declining vaccination rates, timing of the measles, mumps, and rubella vaccine, the influence of vaccine misinformation, and the challenges facing public health officials as they work to restore confidence in vaccination and prevent further transmission. It's a lot, but I really recommend you listen to the full conversation. We've linked it here.
Last week, there were 334 cases of measles, and there were 319 the week before that. Pennsylvania is still really struggling with more than 100 cases in the last 2 weeks, but things are also really heating up in Wisconsin, which had more than 200 cases in that same time period. The other states that we're keeping an extra close eye on are New York, Indiana, and Minnesota. With holiday travel coming up, we'll see in the coming weeks how that influences the spread of measles.
As always, check out our interactive measles map, which is updated at the top of each week, and we've linked it right here.
That is it for today. If you like what you heard, leave us a review wherever you listen to podcasts, and hit subscribe if you haven't already. We'll see you again soon.
This episode was hosted and produced by me, Rachael Robertson. Sound engineering by Greg Laub. Theme music by Palomar. Our guests were MedPage Today reporters Cheryl Clark and Kristen Monaco. Links to their stories are in the show notes.
MedPod Today is a production of MedPage Today. For more information about our show, check out medpagetoday.com/podcasts.
来源:MedPage Today · medpagetoday.com